Cost-Effectiveness of BRCA1 Testing at Time of Obstetrical Prenatal Carrier Screening for Cancer Prevention
(Abstracted from Am J Obstet Gynecol 2024;231:330.e1–330.e14) BRCA1 gene mutations significantly increase the risk of breast, ovarian, and pancreatic cancer. Early interventions, such as screening, chemoprevention, and risk-reducing surgeries—including bilateral mastectomy (RRBM) and salpingo-oophorectomy (rrBSO)—have been shown to lower cancer risk and mortality.
Authors
- Ravi N. Sharaf (ORCID: https://orcid.org/0000-0002-6905-9823)
- June Y. Hou (ORCID: https://orcid.org/0000-0002-6022-0035)
- Jesse Brewer (ORCID: https://orcid.org/0000-0002-4174-6015)
- Muhammad Danyal Ahsan (ORCID: https://orcid.org/0000-0001-8633-8931)
- Melissa Kristen Frey (ORCID: https://orcid.org/0000-0002-6705-1211)
- Jason D. Wright (ORCID: https://orcid.org/0000-0001-6390-825X)
- Luiza Perez (ORCID: https://orcid.org/0000-0002-3710-380X)
- Shayan Dioun
- Malavika Prabhu
Institutions
- Faculty of 1000 (United Kingdom) (GB)
- J.P. Morgan (GB)
Publication Details
- Journal
- Obstetrical & Gynecological Survey
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1097/01.ogx.0001110356.31970.23
- Primary Topic
- BRCA gene mutations in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00